ApoE Pipeline 2016 Review of Apolipoprotein E Market Therapeutics

Aug 12, 2016, 06:00 ET from ReportsnReports

PUNE, India, August 12, 2016 /PRNewswire/ --

ReportsnReports.com adds "Apolipoprotein E (ApoE) - Pipeline Review, H1 2016" market research report providing comprehensive information on Apolipoprotein E (ApoE) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein E (ApoE) targeted therapeutics development and features dormant and discontinued projects.

Complete report on H1 2016 pipeline review of Apolipoprotein E (ApoE) with 15 market data tables and 11 figures, spread across 45 pages is available at http://www.reportsnreports.com/reports/628262-apolipoprotein-e-apoe-pipeline-review-h1-2016.html .

Companies discussed in this Apolipoprotein E (ApoE) Pipeline Review, H1 2016 report include LipimetiX Development, Inc. and ReXceptor Inc. Drug Profiles mentioned in this research report are AEM-28, AEM-2802, AEM-2814, bexarotene, Monoclonal Antibodies to Target ApoE for Alzheimer''s Disease, Recombinant ApoE4 for Dyslipidemia and Small Molecules to Activate ApoE for Alzheimer''s Disease.

Apolipoprotein E (ApoE)  pipeline Target constitutes close to 7 molecules. Out of which approximately 4 molecules are developed by Companies and remaining by the Universities/Institutes. Global Markets Direct's latest report Apolipoprotein E - Pipeline Review, H1 2016, outlays comprehensive information on the Apolipoprotein E (ApoE) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Apolipoprotein E (ApoE) Apolipoprotein E (APOE) is a class of apolipoprotein found in the chylomicron and Intermediate-density lipoprotein (IDLs).  ApoE protein plays important roles in the body, including transporting cholesterol and cholesterol-like molecules, including beta-amyloid, in and out of cells. It serves as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Order a copy of Apolipoprotein E (ApoE) - Pipeline Review, H1 2016 market research report @ http://www.reportsnreports.com/purchase.aspx?name=628262 .

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Furthermore, this report also reviews key players involved in Apolipoprotein E (ApoE) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Apolipoprotein E (ApoE) and reviews pipeline therapeutics for Apolipoprotein E (ApoE) by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Apolipoprotein E (ApoE) therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Apolipoprotein E (ApoE) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Apolipoprotein E (ApoE).

Another newly published market research report titled on Apolipoprotein A-I (ApoA-I) - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Apolipoprotein A-I (ApoA-I), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Apolipoprotein A-I (ApoA-I) and special features on late-stage and discontinued projects. Companies discussed in this research are Arisaph Pharmaceuticals, Inc., Cerenis Therapeutics Holding SA, CSL Limited, Esperion Therapeutics, Inc. and KineMed, Inc.Apolipoprotein A-I (ApoA-I) Pipeline market research report of 57 pages is available at http://www.reportsnreports.com/reports/640459-apolipoprotein-a-i-apoa-i-pipeline-review-h1-2016.html .

Explore more reports on Pharmaceuticals.

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+1 888 391 5441
sales@reportsandreports.com


Connect With Us on:
Facebook: https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https://twitter.com/marketsreports  
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports